Curaleaf Sweetens Aurora Takeover Bid with 25% Higher Valuation
Event summary
- Curaleaf increases takeover offer for Aurora Cannabis to $5.00 per share, an 86% premium over Aurora's unaffected price.
- Enhanced offer includes 33% more cash consideration ($1.00 per share) and 20% higher share consideration (0.4013 Curaleaf shares per Aurora share).
- Combined entity would operate in 17 countries with $1.5B revenue and $350M adjusted EBITDA, targeting $40M in annual cost synergies.
- Offer extension deadline moved to December 4, 2026, despite Aurora's refusal to engage in customary due diligence.
- Curaleaf claims support from significant percentage of Aurora shareholders for the strategic rationale.
The big picture
This aggressive bid reflects the ongoing consolidation in the cannabis sector as major players seek scale to weather regulatory uncertainty and improve profitability. The proposed combination would create a global leader with significant operational reach and cost-saving opportunities, though the lack of cooperation from Aurora's board introduces execution risks. The deal highlights the tension between strategic rationale and governance dynamics in the cannabis industry.
What we're watching
- Regulatory Upside
- How federal cannabis legalization in the U.S. could accelerate the combined entity's growth potential.
- Execution Risk
- Whether Curaleaf can integrate Aurora's operations effectively despite lack of pre-deal due diligence.
- Shareholder Response
- The pace at which Aurora shareholders tender shares given the enhanced offer and extended deadline.
Related topics
